Skip to main content Skip to search Skip to main navigation
News: ICH

ICH: Final Q13 Guideline on Continuous Manufacturing

In Mid-November, the ICH Q13 Guideline on "Continuous Manufacturing of Drug Substances and Drug Products (Step 4)" was finally adopted during the General Assembly of the International Council for Harmonisation (ICH). With the adoption within the ICH organization, the guidelines are considered harmonized and thus represent the current state of science and technology. A concept paper for the Guideline was first submitted in November 2018.

The 46-pages guideline:

  • Builds on existing ICH Quality Guidelines
  • Provides clarification on continuous manufacturing (CM) concepts
  • Describes scientific approaches, and presents regulatory considerations specific to CM of drug substances and drug products
  • Focuses on the integrated aspects of a CM system in which two or more unit operations are directly connected
  • Includes scientific and regulatory considerations for the development, implementation, operation, and lifecycle management of CM.

The introductory Part I of the guideline addresses CM concepts, the scientific approach, and regulatory considerations, such as manufacturing processes, control strategies, batch sizes, product stability, process validation, or the pharmaceutical quality system. Included are sensible recommendations regarding regulatory expectations that provide manufacturers with a flexible approach.

Part II includes five annexes that offer concise explanations and practical examples. These include flowcharts with manufacturing processes and also various examples of how to handle process disturbances:

  • Annex 1: Considerations for CM of drug substances.
  • Annex 2: Considerations for CM of drug products
  • Annex 3: Considerations for CM of drug substances (therapeutic proteins)
  • Annex 4: Considerations for integrated drug substances and drug products CM
  • Annex 5: Perspectives of managing disturbances

Source:

ICH: ICH Q13 on Continuous Manufacturing

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may Also be Interested in the Following Articles

News: ICH

ICH: Adoption of the ICH Q1 Stability Guideline

The Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) met on 17-18 November 2026 in Prague, Czechia for its biannual meeting. ICH announced, among other things, adoption of ICH Q1: Stability Testing of Drug Substances and Drug Products as a final harmonised guideline.
Read more
FDA Expands Sampling and Testing of Marketed Medicines

FDA Expands Sampling and Testing of Marketed Medicines

Through its Enhanced Approach for Sampling and Testing (EAST) program, the US Food and Drug Administration combines rapid analytical techniques with established testing methods. The agency aims to test more medicines from US and overseas manufacturers, detect potential quality issues earlier, and use the findings to inform risk-based inspection planning.
Read more
FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

At the PDA/FDA Joint Regulatory Conference 2026, FDA made it clear that modern equipment alone does not ensure sterility assurance. The article examines GMP deficiencies identified during FDA inspections and the role of facility design in aseptic manufacturing.

Read more
Question of the Week | GMP-Verlag

How is Qualification Carried out in Accordance With the V-model Described in GAMP® 5?

Here's the answer:
Read more
News: Medical Devices

EMA: Harmonisation of Combination-Product Quality Assessment

EMA’s Combination Products Operational Group (COMBO) is working to improve alignment between notified body opinions (NBOps) and pharmaceutical quality assessment, according to its report on the meeting held on 8 October 2026.
Read more
PIC/S: Revision of the Framework for International Cooperation

PIC/S: Revision of the Framework for International Cooperation

PIC/S has revised the framework governing its international cooperation. The updated Pharmaceutical Inspection Co-operation Scheme, PIC/S 1/95 (Rev. 7), was adopted in Istanbul on 2 November 2026 and entered into force on the same day.
Read more
Previous
Next